BACKGROUND: The course of depressive symptoms during and after breast cancer treatment is not well understood. PURPOSE: We identified patient subgroups based on distinct trajectories of depressive symptoms and determined whether subgroups could be distinguished by personal characteristics and coping strategies. METHODS: Breast cancer patients completed the Center for Epidemiologic Studies-Depression Scale on clinically meaningful occasions and during the posttreatment period. The Illness Management Questionnaire was completed prior to treatment. RESULTS: A three-class mixture model provided the best fit to the data. Subgroup membership was significantly (p < .05) associated with marital status, history of depression, and focusing on symptoms. In multivariate analysis, marital status and focusing on symptoms remained significant (p < .05) predictors of subgroup membership. CONCLUSIONS: Distinct trajectories can be identified during and after adjuvant breast cancer therapy. Predictors of these trajectories have implications for addressing depressive symptoms in this clinical population and for future research.
BACKGROUND: The course of depressive symptoms during and after breast cancer treatment is not well understood. PURPOSE: We identified patient subgroups based on distinct trajectories of depressive symptoms and determined whether subgroups could be distinguished by personal characteristics and coping strategies. METHODS:Breast cancerpatients completed the Center for Epidemiologic Studies-Depression Scale on clinically meaningful occasions and during the posttreatment period. The Illness Management Questionnaire was completed prior to treatment. RESULTS: A three-class mixture model provided the best fit to the data. Subgroup membership was significantly (p < .05) associated with marital status, history of depression, and focusing on symptoms. In multivariate analysis, marital status and focusing on symptoms remained significant (p < .05) predictors of subgroup membership. CONCLUSIONS: Distinct trajectories can be identified during and after adjuvant breast cancer therapy. Predictors of these trajectories have implications for addressing depressive symptoms in this clinical population and for future research.
Authors: Michael A Andrykowski; John E Schmidt; John M Salsman; Abbie O Beacham; Paul B Jacobsen Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: D A Solomon; M B Keller; A C Leon; T I Mueller; P W Lavori; M T Shea; W Coryell; M Warshaw; C Turvey; J D Maser; J Endicott Journal: Am J Psychiatry Date: 2000-02 Impact factor: 18.112
Authors: Nancy E Avis; Beverly J Levine; L Douglas Case; Elizabeth Z Naftalis; Kimberly J Van Zee Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-09-16 Impact factor: 4.254
Authors: Larissa N Dooley; Patricia A Ganz; Steve W Cole; Catherine M Crespi; Julienne E Bower Journal: J Affect Disord Date: 2016-03-02 Impact factor: 4.839
Authors: Brian D Gonzalez; Sharon L Manne; Jerod Stapleton; Shannon Myers-Virtue; Melissa Ozga; David Kissane; Carolyn Heckman; Mark Morgan Journal: Support Care Cancer Date: 2016-10-19 Impact factor: 3.603
Authors: Hongjin Li; Anna L Marsland; Yvette P Conley; Susan M Sereika; Catherine M Bender Journal: Biol Res Nurs Date: 2020-01-07 Impact factor: 2.522